- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07951320
Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors (RESET-PsO)
Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Trial
This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.
Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.
Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.
Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.
A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Yi Xiao
- Telefoonnummer: +86 137 8719 1233
- E-mail: xiaoyixy@csu.edu.cn
Studie Contact Back-up
- Naam: Yehong Kuang
- Telefoonnummer: +86 13574171102
- E-mail: yh_927@126.com
Studie Locaties
-
-
-
Shanghai, China
- Shanghai Skin Disease Hospital
-
-
Hunan
-
Changde, Hunan, China
- Changde First People's Hospital
-
Changsha, Hunan, China
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China
- Xiangya Hospital, Central South University
-
Changsha, Hunan, China
- The Third Xiangya Hospital of Central South University
-
-
Liaoning
-
Dalian, Liaoning, China
- Dalian Dermatology Hospital
-
Shenyang, Liaoning, China
- Central Hospital Affiliated to Shenyang Medical College
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Participants must meet all of the following criteria:
-
Understand the study requirements and procedures, voluntarily provide written informed consent, and be willing and able to comply with the protocol.
-
Be male or female and aged 18 to 75 years, inclusive.
-
Have a clinical diagnosis of plaque psoriasis that was moderate to severe before starting the current interleukin-17A (IL-17A) inhibitor.
-
Meet the following prior-treatment and prior-response requirements for secondary treatment failure:
Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).
The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.
A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:
- Recorded Psoriasis Area and Severity Index (PASI) scores demonstrate a reduction of at least 90% from the PASI score before starting that IL-17A inhibitor, corresponding to a PASI90 response.
- Contemporaneous medical records document a static Physician's Global Assessment (sPGA) or Investigator's Global Assessment (IGA) score of 0 or 1, with these categories corresponding to clear or almost clear on the scale used.
- Contemporaneous physician records explicitly document clear or almost clear skin lesions.
- Contemporaneous medical records document that the percentage of body surface area affected by psoriasis (BSA) decreased to 1% or less during treatment with the same current IL-17A inhibitor.
The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.
-
After achieving at least one of the good-response criteria above, have subsequent worsening while continuing the same IL-17A inhibitor, with PASI ≥3 and sPGA ≥2 at both screening and the Week 0 baseline visit, and an investigator judgment that a change in treatment strategy is needed. The investigator must review the prior response, worsening, and treatment records to confirm their temporal sequence and determine that the current worsening is not primarily attributable to treatment interruption or substantial nonadherence.
-
Have dyslipidemia with fasting low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and <4.9 mmol/L, without atherosclerotic cardiovascular disease (ASCVD).
-
Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. Male and female participants of reproductive potential must agree to use highly effective contraception throughout the study and for 30 days after the last dose of study drug. Participants must also comply with the contraception requirements for their background IL-17A inhibitor. Any longer contraception periods specified in the applicable prescribing information or investigator's brochure must also be observed.
-
Be willing to complete the required protocol examinations and assessments. Participation in optional assessments is voluntary, and declining them does not affect eligibility for the main study.
Exclusion Criteria:
Participants meeting any of the following criteria are excluded:
- A diagnosis of non-plaque psoriasis at screening or baseline, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.
- Severe hypersensitivity to an active ingredient or any excipient of the study drugs.
- Concomitant malignancy.
- Any previous or current PCSK9-targeted therapy, including PCSK9 monoclonal antibodies or PCSK9-targeting small interfering RNA (siRNA) drugs, such as inclisiran.
- Current treatment at screening with other lipid-lowering drugs, such as statins or ezetimibe. Clinically necessary lipid-lowering treatment must not be discontinued to meet study eligibility criteria.
- Treatment with a biologic targeting a pathway other than IL-17A, or a small-molecule targeted drug, within 4 weeks before screening.
- Clinically significant active disease, such as active tuberculosis or active hepatitis.
- Participation in another clinical trial with use of a trial-related drug within 3 months before screening.
- Pregnancy, breastfeeding, or planned pregnancy during the study; or unwillingness of a male or female participant to use contraception.
- Major surgery within 3 months before screening or planned major surgery during the study.
- Renal impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² during screening.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >2 times ULN.
- New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction <30%.
- Previously or currently diagnosed ASCVD, including coronary heart disease, ischemic stroke, or atherosclerotic peripheral artery disease; or another type of stroke within 3 months before randomization.
- A need to promptly initiate, continue, or intensify lipid-lowering drug therapy, based on an assessment of overall ASCVD risk and lipid-lowering treatment needs according to the Chinese Guidelines for Lipid Management (2023), such that treatment should not be delayed during the 16-week controlled treatment period.
- Any other condition that, in the investigator's judgment, makes participation inappropriate.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Recaticimab Plus Background IL-17A Inhibitor
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit. |
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments. |
|
Placebo-vergelijker: Placebo Plus Background IL-17A Inhibitor
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit. |
Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments. Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants achieving PASI75 at Week 16
Tijdsspanne: Week 16
|
PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline. |
Week 16
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean percentage improvement from baseline in sPGA × BSA at Week 16
Tijdsspanne: Baseline (Week 0) and Week 16
|
sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value. |
Baseline (Week 0) and Week 16
|
|
Mean change from baseline in PASI score
Tijdsspanne: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease. |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Mean percentage improvement from baseline in PASI score
Tijdsspanne: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement. |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI50
Tijdsspanne: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI90
Tijdsspanne: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants achieving PASI100
Tijdsspanne: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with a 100% reduction in PASI from the Week 0 randomization baseline. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Percentage of participants with sPGA 0 or 1
Tijdsspanne: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4. |
Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Change from baseline in skin itch Numeric Rating Scale score
Tijdsspanne: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch). |
Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
|
|
Change from baseline in Dermatology Life Quality Index score
Tijdsspanne: Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
|
Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life. |
Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
|
|
Percentage change from baseline in low-density lipoprotein cholesterol
Tijdsspanne: Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
|
Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement. |
Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
|
|
Participants with treatment-emergent adverse events
Tijdsspanne: From the first study dose through Week 36
|
Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit. |
From the first study dose through Week 36
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Algemene publicaties
- Zimerman A, Kunzler ALF, Weber BN, Ran X, Murphy SA, Wang H, Honarpour N, Keech AC, Sever PS, Sabatine MS, Giugliano RP. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial. Circulation. 2025 May 20;151(20):1467-1476. doi: 10.1161/CIRCULATIONAHA.124.072756. Epub 2025 Apr 21.
- Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MA-DER-IV-050
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .